HUE048912T2 - Mikronizált cisztint tartalmazó szilárd gyógyszerformák - Google Patents

Mikronizált cisztint tartalmazó szilárd gyógyszerformák

Info

Publication number
HUE048912T2
HUE048912T2 HUE13826599A HUE13826599A HUE048912T2 HU E048912 T2 HUE048912 T2 HU E048912T2 HU E13826599 A HUE13826599 A HU E13826599A HU E13826599 A HUE13826599 A HU E13826599A HU E048912 T2 HUE048912 T2 HU E048912T2
Authority
HU
Hungary
Prior art keywords
dosage form
solid dosage
cytisine
micronized
micronized cytisine
Prior art date
Application number
HUE13826599A
Other languages
English (en)
Inventor
Hanna Wahl
Marek Dabrowa
Piotr Kulazinski
Original Assignee
Aflofarm Farm Polska Sp Z O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50730669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE048912(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aflofarm Farm Polska Sp Z O O filed Critical Aflofarm Farm Polska Sp Z O O
Publication of HUE048912T2 publication Critical patent/HUE048912T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE13826599A 2012-11-19 2013-11-19 Mikronizált cisztint tartalmazó szilárd gyógyszerformák HUE048912T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401676A PL220354B1 (pl) 2012-11-19 2012-11-19 Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania

Publications (1)

Publication Number Publication Date
HUE048912T2 true HUE048912T2 (hu) 2020-08-28

Family

ID=50730669

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13826599A HUE048912T2 (hu) 2012-11-19 2013-11-19 Mikronizált cisztint tartalmazó szilárd gyógyszerformák

Country Status (16)

Country Link
US (1) US9387172B2 (hu)
EP (1) EP2919761B1 (hu)
AU (1) AU2013346363B2 (hu)
CL (1) CL2015001343A1 (hu)
CY (1) CY1122947T1 (hu)
DK (1) DK2919761T3 (hu)
ES (1) ES2793527T3 (hu)
HR (1) HRP20200642T1 (hu)
HU (1) HUE048912T2 (hu)
LT (1) LT2919761T (hu)
NZ (1) NZ708199A (hu)
PL (1) PL220354B1 (hu)
PT (1) PT2919761T (hu)
RS (1) RS60249B1 (hu)
SI (1) SI2919761T1 (hu)
WO (1) WO2014076680A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL408608A1 (pl) 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CA3070055A1 (en) * 2017-07-24 2019-01-31 Achieve Pharma Uk Limited Cytisine salts
EP3598968A1 (en) 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG65536B1 (bg) * 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
US20060211649A1 (en) 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
KR20110071008A (ko) 2008-10-14 2011-06-27 맥닐 에이비 다중 부분 경구내 투여량 형태 및 그의 용도
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties

Also Published As

Publication number Publication date
CL2015001343A1 (es) 2015-10-23
SI2919761T1 (sl) 2020-08-31
PL401676A1 (pl) 2014-05-26
LT2919761T (lt) 2020-05-25
RS60249B1 (sr) 2020-06-30
AU2013346363B2 (en) 2018-08-09
NZ708199A (en) 2018-10-26
HRP20200642T1 (hr) 2020-09-04
ES2793527T3 (es) 2020-11-16
WO2014076680A1 (en) 2014-05-22
CY1122947T1 (el) 2021-10-29
US9387172B2 (en) 2016-07-12
EP2919761A1 (en) 2015-09-23
PL220354B1 (pl) 2015-10-30
US20150342884A1 (en) 2015-12-03
DK2919761T3 (da) 2020-11-02
PT2919761T (pt) 2020-05-18
EP2919761B1 (en) 2020-01-15
AU2013346363A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
HK1209638A1 (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
IL273076A (en) Solid dosage form
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1205146A1 (en) Pharmaceutical formulation
ZA201405797B (en) Pharmaceutical dosage form
HK1205679A1 (en) Nicotine formulation
PT2919761T (pt) Forma de dosagem sólida compreendendo citisina micronizada
GB201218012D0 (en) Dosage forms
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
HK1209339A1 (en) Pharmaceutical formulations
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
ZA201502354B (en) Pharmaceutical dosage form
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
IL234771B (en) Nicotine formulation
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions